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Background 
Both Foradil Aerolizer (formoterol fumarate 
inhalation powder), a long-acting, selective beta-2 
adrenergic agonist, and Spiriva HandiHaler 
(tiotropium bromide inhalation powder), a long-
acting anticholinergic bronchodilator, are supplied 
as powder in a capsule-loaded dosage form.1  In 
Canada, Intal Spincaps (sodium cromoglycate), a 
mast cell stabilizer, is also supplied in a capsular 
form.2  These capsules are intended only for 
loading into the brand name dry-inhalation device.  
Because these capsules look like capsules for oral 
administration, accidental oral administration can 
occur. 
 
Commentary 
The FDA has received reports of 
misadministration of these capsules.  Thirty cases 
of oral administration of Foradil inhalation 
capsules and two cases of oral administration of 
Spiriva inhalation capsules have been reported.3   
Though very few of these reports indicated 
adverse outcomes, inappropriate administration 
obviously results in decreased therapeutic 
outcomes.  One case reported difficulty in 
breathing and in another case the patient required 
hospitalization due to exacerbation of chronic 
obstructive pulmonary disease.  Oral 
administration of these capsules resulted because 
the packaging and labeling did not readily display 
“not for oral use” warnings.   
Manufacturers are currently revising package 
and product labels to assure safe and appropriate 
administration.  It is not known when these 
products with revised labeling will reach 
pharmacies.   
Whenever the inhalation capsules are separated 
from the inhalation device, the potential for oral 
administration is increased.  Healthcare 
professionals should affix supplemental warning 
labels to capsules whenever the inhalation 
capsules are separated from devices.  Patients 
should be counseled to store the capsules with the 
inhalers to avoid confusion and they should be 
shown how to correctly load the capsules and use 
the inhaler.  
Report any cases of misadministration.  In the 
US, call the FDA MEDWATCH program at 1-
800-FDA-1088. The MEDWATCH program is 
also available on-line at www.fda.gov/medwatch.  
Or report to the USP Medication Errors Reporting 
Program in cooperation with the Institute for Safe 
Medication Practices at 1-800-23-ERROR or at 
www.usp.org/patientSafety/reporting/mer.html.  
In Canada, call the Canadian Adverse Drug 
Reaction Monitoring Program at 1-866-234-2345.  
The Canadian adverse reaction reporting form can 
be found at: http://www.hc-sc.gc.ca/hpfb-
dgpsa/tpd-dpt/adverse_e.pdf.  It should be 
completed and faxed to 1-866-678-6789.  You can 
also contact the Institute for Safe Medication 
Practices (ISMP) by calling 215-947-7797 or 
reporting on-line at www.ismp.org/Pages/ 
communications.asp.  
 
Sound-Alike, Look-Alike Concern 
Recently, a sound-alike, look-alike Spiriva-
Inspra concern was reported to the Institute for 
Safe Medication Practices (ISMP).4  In the 
reported case, Spiriva 25 mg orally daily was 
ordered.  A pharmacist intercepted the order due 
to the oral route of administration and clarified the 
order to Inspra 25 mg orally daily.  
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Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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